Related Experiment Video
Updated: Feb 8, 2026

Probiotic Studies in Neonatal Mice Using Gavage
Published on: January 27, 2019
Para-probiotics for Preterm Neonates-The Next Frontier
Girish Deshpande1,2, Gayatri Athalye-Jape3, Sanjay Patole4
1Department of Neonatology, Nepean Hospital, Kingswood, NSW 2747, Australia. girish.deshpande@health.nsw.gov.au.
Insights
Paraprobiotics, or non-viable microbial cells, show promise as safe alternatives to probiotics for preventing necrotizing enterocolitis in preterm neonates. Further research is needed to confirm their efficacy and safety in this vulnerable population.
Area of Science:
- Neonatal Medicine
- Microbiology
- Gastroenterology
Background:
- Probiotics are recommended for preterm neonates to prevent necrotizing enterocolitis, mortality, and late-onset sepsis.
- Concerns regarding probiotic sepsis, inflammation, and antibiotic resistance limit widespread adoption.
- The viability of probiotics is questioned, prompting exploration of alternatives.
Purpose of the Study:
- To evaluate paraprobiotics as potentially safer alternatives to probiotics in preterm neonates.
- To address safety concerns associated with live probiotic administration in vulnerable infants.
- To explore a new frontier in neonatal gut health management.
Main Methods:
- Review of current evidence on probiotics and paraprobiotics in preterm neonates.
- Analysis of safety concerns, including probiotic sepsis and translocation risks.
- Consideration of the definition and function of paraprobiotics (non-viable microbial cells or extracts).
Main Results:
- Paraprobiotics are suggested as potentially safe alternatives to live probiotics for preterm infants.
- Non-viable microbial cells may offer benefits without the risks of live bacteria translocation.
- Current evidence supports further investigation into paraprobiotics' role.
Conclusions:
- Paraprobiotics present a promising, potentially safer, alternative for preterm neonate gut health.
- High-quality clinical trials, including randomized controlled trials, are essential.
- Further research is warranted to establish the efficacy and safety of paraprobiotics in this population.
Abstract:
Current evidence supports the use of probiotics in preterm neonates for prevention of necrotizing enterocolitis, mortality and late onset sepsis. Despite the strong evidence, the uptake of this intervention has not been universal due to concerns including probiotic sepsis, pro-inflammatory response and transmission of antibiotic resistance. Critically ill extremely preterm neonates with potentially compromised gut integrity are at higher risk of probiotic sepsis due to translocation. In most countries, probiotics are sold as food supplements with poor quality control. The traditional definition of probiotics as “live microorganisms” has been challenged as many experts have questioned the importance of viability in the context of the beneficial effects of probiotics. Paraprobiotics (ghost probiotics), are defined as non-viable microbial cells (intact or broken) or crude cell extracts (i.e., with complex chemical composition), which, when administered (orally or topically) in adequate amounts, confer a benefit on the human or animal consumer. Current evidence indicates that paraprobiotics could be safe alternatives to probiotics in preterm neonates. High-quality pre-clinical and clinical studies including adequately powered randomised controlled trials (RCTs) are warranted in preterm neonates to explore this new frontier.
Related Concept Videos
Directing Effect of Substituents: ortho–para-Directing Groups
ortho–para-Directing Deactivators: Halogens
ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH3

